DRUG METABOLISM AND DISPOSITION
Scope & Guideline
Your Gateway to Cutting-Edge Drug Research
Introduction
Aims and Scopes
- Pharmacokinetics and Drug Disposition:
Research articles often explore the pharmacokinetics of drugs, including absorption, distribution, metabolism, and excretion (ADME). This encompasses both in vivo and in vitro studies, utilizing physiologically based pharmacokinetic modeling to predict human responses. - Drug-Metabolizing Enzymes:
A key focus is on cytochrome P450 enzymes and other drug-metabolizing enzymes, examining their roles in drug metabolism, genetic polymorphisms, and variations in enzymatic activity across different populations. - Transport Mechanisms:
The journal highlights studies on drug transporters, including their regulation, function, and impact on drug absorption and disposition, emphasizing the interplay between metabolic enzymes and transport systems. - Toxicology and Drug Safety:
Research often addresses the toxicological aspects of drug metabolism, including the identification of metabolites that may contribute to adverse drug reactions and strategies for mitigating these effects. - Clinical Relevance and Biomarkers:
The journal emphasizes the clinical implications of drug metabolism research, including the identification of biomarkers for drug efficacy and safety, and the impact of genetic and environmental factors on individual drug responses. - Innovative Methodologies:
The use of novel experimental approaches, such as high-throughput screening, advanced analytical techniques, and computational modeling, is frequently reported to enhance our understanding of drug metabolism and disposition.
Trending and Emerging
- Precision Medicine and Pharmacogenomics:
There is an increasing emphasis on precision medicine and pharmacogenomics, as studies investigate how genetic variations affect drug metabolism, efficacy, and safety, paving the way for individualized therapeutic strategies. - Physiologically Based Pharmacokinetic (PBPK) Modeling:
The use of PBPK modeling is on the rise, allowing for more accurate predictions of drug behavior in humans based on in vitro data, enhancing the relevance of preclinical studies to clinical outcomes. - Gut Microbiome Interactions:
Emerging research on the role of the gut microbiome in drug metabolism is gaining traction, highlighting how microbial metabolites can influence drug efficacy and toxicity. - Transporter Biology and Drug Disposition:
There is a growing focus on the roles of transporters in drug absorption and disposition, particularly how they interact with metabolic enzymes and their implications for drug-drug interactions. - Innovative Drug Delivery Systems:
Research into novel drug delivery systems, such as nanoparticles and liposomal formulations, is trending, reflecting a broader interest in optimizing drug bioavailability and therapeutic outcomes. - Environmental and Dietary Influences:
Recent studies are increasingly examining how environmental factors and dietary components affect drug metabolism, emphasizing the importance of lifestyle in pharmacokinetic profiles.
Declining or Waning
- Traditional In Vitro Models:
There seems to be a waning interest in conventional in vitro models for drug metabolism, such as using only liver microsomes or hepatocytes, as researchers increasingly adopt more sophisticated systems like 3D cell cultures or organ-on-chip technologies. - Non-Cytochrome P450 Enzyme Studies:
Research specifically focused on non-cytochrome P450 enzymes appears to be less frequent, suggesting a shift towards more detailed investigations of cytochrome P450 enzymes and their interactions with other metabolic pathways. - General Drug Interaction Studies:
There is a noticeable decline in the publication of generic drug-drug interaction studies without a specific focus on mechanisms, as the field moves towards more nuanced explorations of specific pathways and genetic influences. - Animal Models for Drug Metabolism:
The reliance on traditional animal models for drug metabolism studies is decreasing, with a growing emphasis on humanized models and in vitro systems that better predict human responses. - Historical Perspectives:
Papers providing broad historical overviews on drug metabolism topics are becoming less common, indicating a shift towards more focused, cutting-edge research that addresses current challenges in drug metabolism and pharmacokinetics.
Similar Journals
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
Fostering Collaboration in Pharmacological StudiesJOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, published by Springer/Plenum Publishers, stands as a vital resource in the field of pharmacology. With an ISSN of 1567-567X and an E-ISSN of 1573-8744, this journal is well-regarded within the academic community, as reflected in its Q2 ranking in the 2023 Scopus category for Pharmacology. Spanning years from 1996 to 2024, it serves as a comprehensive platform for cutting-edge research on the interactions of drugs within the body, their effects, and the underlying pharmacological mechanisms. The journal provides a critical avenue for dissemination of significant research findings, with a focus on enhancing understanding in pharmacokinetics, pharmacodynamics, and their implications in therapeutic practices. Targeting an audience of researchers, professionals, and students, the journal emphasizes high-quality manuscripts that contribute to the advancement of knowledge in pharmacology. Although currently not an open access journal, it maintains a strong commitment to promoting scientific communication and collaboration.
PHARMAZIE
Pioneering insights in toxicology and pharmaceutics.PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.
Drug Metabolism and Pharmacokinetics
Unlocking the Secrets of Xenobiotic ProcessesDrug Metabolism and Pharmacokinetics is a premier academic journal committed to advancing the understanding of drug metabolism processes and pharmacokinetic principles critical to the development of therapeutics. Published by the Japanese Society for the Study of Xenobiotics, this journal has established itself as a vital resource within Pharmaceutical Science and Pharmacology, achieving a respectable Q2 ranking in the latest 2023 metrics. Spanning from 2002 to 2024, the journal publishes original research articles, reviews, and insights that address contemporary issues in xenobiotic metabolism and pharmacologic practices. With its ISSN of 1347-4367 and E-ISSN of 1880-0920, Drug Metabolism and Pharmacokinetics is indexed in leading databases, enhancing its visibility and accessibility for researchers, professionals, and students alike. By fostering a rigorous scientific dialogue, the journal plays an essential role in shaping the future of pharmacology and pharmaceutical sciences.
International Journal of Pharmacology
Innovating Insights in Drug Development and SafetyWelcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.
XENOBIOTICA
Exploring the Impact of Chemicals on Health and Environment.XENOBIOTICA is a premier journal in the field of pharmacology and toxicology, published by Taylor & Francis Ltd. With an ISSN of 0049-8254 and E-ISSN 1366-5928, this journal has been at the forefront of research since 1971, providing critical insights and advancements up until 2024. It is recognized for its rigorous peer-reviewed content, occupying a third quartile ranking across various categories including Biochemistry, Health, Toxicology, and Pharmacology as of 2023. The journal serves as a pivotal platform for disseminating innovative findings that address the impact of xenobiotics on health and the environment, making it an essential resource for researchers, professionals, and students engaged in these multidisciplinary fields. While it does not currently offer open access, it is widely respected for its contribution to science, evidenced by its Scopus rankings across different areas of study. The journal encourages submissions that push the boundaries of knowledge and transform our understanding of the effects of chemical substances on living organisms.
Clinical Pharmacology in Drug Development
Elevating drug development through peer-reviewed excellence.Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Connecting Basic Science with Clinical ApplicationsBASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
Elevating Scientific Dialogue in Health ResearchCLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, published by WILEY, is a premier journal that serves as a vital resource for researchers, professionals, and students in the fields of pharmacology and physiology. With ISSN 0305-1870 and E-ISSN 1440-1681, this journal has established itself as a significant contributor to scientific dialogue since its inception in 1974. Currently spanning until 2024, it consistently publishes cutting-edge research addressing both experimental and clinical advancements in pharmacology and physiology. Recognized for its quality, it holds a Q2 ranking in the 2023 Pharmacology category and notable Q3 rankings in both Physiology and Medical Physiology. The journal's coverage of topical issues not only ensures a robust platform for innovative findings but also fosters collaborations across disciplines. Although not an Open Access journal, its curated content is invaluable for advancing knowledge, as evidenced by its solid Scopus rankings, which place it within the top percentiles of its field. Engaging with this journal means staying at the forefront of research that shapes clinical practices and experimental methodologies.
Ars Pharmaceutica
Fostering collaboration for transformative pharmaceutical insights.Ars Pharmaceutica is a distinguished open-access journal published by UNIV GRANADA, EDITORIAL, that has been at the forefront of pharmaceutical sciences since its establishment. With ISSN 0004-2927 and E-ISSN 2340-9894, this journal aims to disseminate high-quality research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of the field. With a historical scope that spans from 1980 to 2017, it has played a pivotal role in shaping the discourse surrounding pharmaceutical science and its intersection with the arts and humanities. Although currently ranked within the 13th percentile in Scopus for Pharmaceutical Science and the 11th percentile for History and Philosophy of Science, Ars Pharmaceutica continues to uphold its commitment to academic excellence and innovation. By providing a platform for open-access research, it encourages collaboration and knowledge sharing among researchers, professionals, and students, thus enhancing the broader understanding of pharmaceutical developments and their societal implications.
DRUGS IN R&D
Advancing pharmacological frontiers through open access research.DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.